Circulating Cancer Cells/Macrophage HYbrid Cells in Patients With Breast Cancer.

Institut Claudius Regaud61 enrolled

Overview

Pilot, prospective, monocentric study aimed at evaluating the rate of patients with circulating cancer cell/macrophage hybrid cells in the peripheral blood. The study will be conducted on a population of patients with breast cancer (regardless of stage of the disease and the immunohistochemical subtype). For each included patient, blood samples will be taken and tumor specimens will be collected for the study. At the end of the blood collection, the patient will have completed his participation in the study.

Study Type

INTERVENTIONAL

Allocation

Purpose

OTHER

Masking

NONE

Enrollment

Conditions

Breast Cancer

Interventions

Patients with breast cancer (stage I, II III or IV)OTHER

Blood samples will be collected at different times: * at Baseline for all patients with breast cancer: before initiation of treatment (i.e. before initiation of planned treatment for stage I to III patients and before any new line of treatment for stage IV patients); * at the time of disease progression (or at 12 months in absence of progression) for patients with metastatic breast cancer (stage IV) For each patient a tumor sample from the initial diagnosis of the disease (i.e. primary tumor +/- biopsy of a metastasis) will be collected (archived tumor block) for the study.

Eligibility

Sex: FEMALEMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patient with breast cancer of any stage (stage I, II, III or IV) and any immunohistochemical subtype (triple-negative, HR+/HER2-negative or HER2-positive). 2. Patient not yet initiated on specific treatment for the stage of breast cancer at inclusion. 3. Available tumor sample (archived tumor block) : initial tumor or metastasis depending on the stage of the disease and availability. 4. Age ≥ 18 years old. 5. Patient affiliated to a Social Health Insurance in France. 6. Patient having signed informed consent prior to inclusion in the study and prior to any specific study procedure. Exclusion Criteria: 1. Associated pathology(ies) that may prevent the proper conduct of the procedure under consideration. 2. Pregnant or breastfeeding woman. 3. Any psychological, family, geographical or sociological condition that prevents compliance with the medical follow-up and/or procedures of the study protocol. 4. Patient who has forfeited his/her freedom by administrative or legal award or who is under legal protection (curatorship and guardianship protection of justice). 5. Patient who has presented another solid tumor (except breast or cervix carcinoma in situ) within 5 years.

Locations (1)

Institut Universitaire du Cancer de Toulouse - Oncopole

Toulouse, France

Outcomes

Primary Outcomes

Rate of patients with cancer cell / macrophage hybrid cells in peripheral blood defined as the ratio of the number of patients with hybrid cells to the total number of patients.

Time frame: 20 months after the study start

Secondary Outcomes

Quantification of circulating hybrid cells in peripheral blood by automatic measurement (Cell Counter Corning) and expressed in number of cells / millilitre of blood.

Time frame: 20 months after the study start

Progression-free survival (PFS) defined as the time from the date of inclusion to the date of progression or death from any cause.

Time frame: 20 months after the study start

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.